Nov 1, 2022

Benzinga By Globe Newswire Reported positive data from EPIPHAST II trial comparing AQST-109 (epinephrine sublingual film) to EpiPen 0.3mg (single dose) and AQST-109 to epi 0.3mg IM injection (repeat dose) Scheduled End-of-Phase 2 (EoP2) meeting with FDA on AQST-109 for fourth quarter 2022 Generated over $25 million in near-term non-dilutive funding through multiple transactions Announces strategic decision to explore US out-licensing opportunities for Libervant (diazepam buccal film) Confirms full-year revenue and earnings guidance Hosts investment community conference call on November 2, 2022 AD AD WARREN, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. AQST, a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying complex delivery methods, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent developments in its business. We have made significant progress over the last few months in streamlining our business, reducing expenses, and creating a path to an improved financial position, while continuing to rapidly advance our lead asset, AQST-109, said Daniel Barber, Chief Executive Officer of Aquestive. We continue to believe in the real-world utility of epinephrine sublingual film and look forward to reviewing the data and pivotal program plan with the FDA in our upcoming EoP2 meeting. At the same time, we continue to engage with the FDA on Libervant and are prioritizing the exploration of out-licensing this important product for North America. In the meantime, our manufacturing business continues to generate strong results, thereby allowing us to focus on reducing and potentially refinancing our corporate debt as we progress into 2023.